참고문헌
- Abbas S, Lugthart S, Kavelaars FG, et al (2010). Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood, 116, 2122-6. https://doi.org/10.1182/blood-2009-11-250878
- Ahmad F, Mohota R, Sanap S, et al (2014). Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients. Asian Pac J Cancer Prev, 15, 1247-53. https://doi.org/10.7314/APJCP.2014.15.3.1247
- Ahmad F, Mandava S, Das BR (2009). Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population. Hematol Oncol, 27, 90-7. https://doi.org/10.1002/hon.883
- Amary MF, Bacsi K, Maggiani F, et al (2011). IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol, 224, 334-43. https://doi.org/10.1002/path.2913
- Borger DR, Tanabe KK, Fan KC, et al (2012). Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist, 17, 72-9. https://doi.org/10.1634/theoncologist.2011-0386
- Cairns RA, Iqbal J, Lemonnier F, et al (2012). IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood, 119, 1901-3. https://doi.org/10.1182/blood-2011-11-391748
- Chotirat S, Thongnoppakhun W, Promsuwicha O, et al (2012). Molecular alterations of Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. J Hematol Oncol, 5, 1-10. https://doi.org/10.1186/1756-8722-5-1
- Chou WC, Hou HA, Chen CY, et al (2010). Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood, 115, 2749-54. https://doi.org/10.1182/blood-2009-11-253070
- Conway O'Brien E, Prideaux S, Chevassut T (2014). The epigenetic landscape of acute myeloid leukemia. Adv Hematol, 2014, 1-15.
- Dang L, Jin S, Su SM (2010). IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med, 16, 387-397. https://doi.org/10.1016/j.molmed.2010.07.002
- Dang L, White DW, Gross S, et al (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 462, 739-44. https://doi.org/10.1038/nature08617
- Dohner H, Gaidzik VI (2011). Impact of genetic features on treatment decisions in AML. Hematology Am Soc Hematol Educ Program, 2011, 36-42. https://doi.org/10.1182/asheducation-2011.1.36
- Figueroa ME, Abdel-Wahab O, Lu C, et al (2010). Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell, 18, 553-67. https://doi.org/10.1016/j.ccr.2010.11.015
- Ghiam AF, Cairns RA, Thoms J, et al (2012). IDH mutation status in prostate cancer. Oncogene, 31, 3826. https://doi.org/10.1038/onc.2011.546
- Henegariu O, Heerema NA, Lowe Wright L, et al (2001). Improvements in cytogenetic slide preparation: Controlled chromosome spreading, chemical aging and gradual denaturing. Cytometry, 43, 101-9. https://doi.org/10.1002/1097-0320(20010201)43:2<101::AID-CYTO1024>3.0.CO;2-8
- Ho PA, Kopecky KJ, Alonzo TA, et al (2011). Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the children's oncology group and SWOG. Blood, 118, 4561-6. https://doi.org/10.1182/blood-2011-04-348888
- Im AP, Sehgal AR, Carroll MP, et al (2014). DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia, 28, 1774-83. https://doi.org/10.1038/leu.2014.124
- Ley TJ, Miller C, Ding L, et al (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med, 368, 2059-74. https://doi.org/10.1056/NEJMoa1301689
- Lin J, Qian J, Yao DM, et al (2011). Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis. Clin Biochem, 44, 779-83. https://doi.org/10.1016/j.clinbiochem.2011.04.014
- Losman JA, Kaelin WG Jr (2013). What a difference a hydroxyl makes:mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev, 27, 836-52. https://doi.org/10.1101/gad.217406.113
- Marcuccii G, Maharry K, Wu YZ, et al (2010). IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol, 28, 2348-55. https://doi.org/10.1200/JCO.2009.27.3730
- Mardis ER, Ding L, Dooling DJ, et al (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med, 361, 1058-66. https://doi.org/10.1056/NEJMoa0903840
- Parsons DW, Jones S, Zhang X, et al (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321, 1807-12. https://doi.org/10.1126/science.1164382
- Paschka P, Schlenk RF, Gaidzik VI, et al (2010). IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol, 28, 3636-43. https://doi.org/10.1200/JCO.2010.28.3762
- Patel KP, Ravandi F, Ma D, et al (2011). Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol, 135, 35-45. https://doi.org/10.1309/AJCPD7NR2RMNQDVF
- Patel JP, Gonen M, Figueroa ME, et al (2012). Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med, 366, 1079-89. https://doi.org/10.1056/NEJMoa1112304
- Patnaik MM, Hanson CA, Hodnefield JM, et al (2012). Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients, Leukemia, 26, 101-5. https://doi.org/10.1038/leu.2011.298
- Schnittger S, Haferlach C, Ulke M, et al (2010). IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood, 116, 5486-96. https://doi.org/10.1182/blood-2010-02-267955
- Shaffer LG, McGowan-Jordan J, Schmid M (eds). ISCN 2013: An International System for Human Cytogenetic Nomenclature (2013). Basel, Karger, 2013.
- Shih AH, Abdel-Wahab O, Patel JP,et al(2012). The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer, 12, 599-612. https://doi.org/10.1038/nrc3343
- Van den Bent MJ, Dubbink HJ, Marie Y, et al (2010). IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European organization for research and treatment of cancer brain tumor group. Clin Cancer Res, 16, 1597-604. https://doi.org/10.1158/1078-0432.CCR-09-2902
- Wagner K, Damm F, Gohring G, et al (2010). Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol, 28, 2356-64. https://doi.org/10.1200/JCO.2009.27.6899
- Ward PS, Patel J, Wise DR, et al (2010). The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell, 17, 225-34. https://doi.org/10.1016/j.ccr.2010.01.020
-
Xu W, Yang H, Liu Y, et al (2011). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of
${\alpha}$ -ketoglutarate-dependent dioxygenases. Cancer Cell, 19, 17-30. https://doi.org/10.1016/j.ccr.2010.12.014 - Xu X, Zhao J, Xu Z,et al (2004). Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem, 279, 33946-57. https://doi.org/10.1074/jbc.M404298200
- Yamaguchi S, Iwanaga E, Tokunaga K, et al (2014). IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation. Eur J Haematol, 92, 471-7. https://doi.org/10.1111/ejh.12271
- Zhang Y, Wei H, Tang K,et al(2012). Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia. Genet Test Mol Biomarkers, 16, 991-5. https://doi.org/10.1089/gtmb.2011.0323
- Zhang Y, Wei H, Wang M, et al (2011). Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients. Leuk Res, 35, 1301-6. https://doi.org/10.1016/j.leukres.2011.01.019
- Zou Y, Zeng Y, Zhang DF, et al (2010). IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochem Biophys Res Commun, 402, 378-83. https://doi.org/10.1016/j.bbrc.2010.10.038